Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis.
Fredrik Nils AlbachChristian GeierChristian KeicherMaximilian G PoschStephan J SchreiberGerald GrützLevent AkyüzXiaodong LuoAnnaig Le-HalperePhilippe TruffinetFrank WagnerPublished in: Neurology and therapy (2024)
NCT02282826, NCT02977533, NCT02313285.